<strong>We care</strong> about patients.

We care about patients.

BiOkuris has developed the next generation of medical nutrition products tailored to the unmet medical needs of patients with chronic intestinal diseases such as IBD, IBS and Candidiasis.

We believe that patients deserve specific, safe, effective, and science-driven treatments that reduce their daily burden and help them to restore balance.

Our solutions have been specifically designed to improve both the physiopathology and quality of life for the millions of patients living with chronic intestinal diseases.

Our innovative platform

We target unmet medical needs in gut health.

Inflammatory Bowel Diseases (IBD)

40% of Crohn’s disease and ulcerative colitis patients with long-standing remission continue to experience IBS-like symptoms.

Such ‘IBS-like symptoms’ in IBD patients need to be both comprehensively and specifically targeted to fully satisfy patients’ expectations and radically improve their quality of life.

Irritable Bowel Syndrome (IBS)

Affects 10-20% of the population

BiOkuris is committed to providing targeted, clinically-proven solutions for IBS patients, ensuring a complete and multifactorial effect on their physiopathology, thereby improving their quality of life.

Candidiasis

Occurring in 75% of women at least once in their lives

As the gut is the source of Candida albicans, targeting this commensal in the gut itself could reduce, even prevent, fungal infections in millions of people each year.

<strong>We care</strong> about patients.

Our innovative platform

Two patented ingredients, with multiple action mechanisms

BiOkuris is made using two proprietary active ingredients that are derived from nature, vegan, safe, and non-GMO, both manufactured in Belgium.

We have already yielded exceptional results via multiple in-vitro, in-vivo, and human clinical trials that have confirmed its positive effect on:

  • Intestinal hypersensitivity
  • Inflammation
  • Leaky gut syndrome
  • Gut microbiota homeostasis
  • Chelation of bile acids and various xenobiotics

Three products at a clinical stage

The company is now working on developing targeted solutions based on our proprietary ingredients and selected complementary technologies for each of the three identified unmet medical needs: IBD’s with IBS-like symptoms, IBS, and Candidiasis.

The products are being developed as medical foods and food supplements, allowing patients to play an active role in their treatment and take back control of their balance.

For more information or to enquire about co-development and commercial opportunities, please get in touch.

About us

Our company is located near Liege, in Belgium, and we benefit from the rich ecosystem of the “biotech-pharma valley” in Wallonia, allowing us to get access to the best resources to develop our projects. Most importantly, BiOkuris is part of the KitoZyme Group, who for the last 20 years has specialized in the design and manufacturing of biopolymers for Health & Nutrition, Agriculture and Personal Care.

Kitozyme

KitoZyme is a global leader of natural ingredients derived from fungi, and has obtained multiple market authorizations and certifications, including GRAS, Novel Food, Medical Devices.

The company has built a strong scientific background and IP portfolio to support its applications in the markets that it serves.

In particular, since 2008, KitoZyme has developed a strong knowledge in Gastro-Intestinal Health, and based on breakthrough results obtained in 2017-2020, we decided to create a dedicated company, BiOkuris, to continue and strengthen the developments in this field.

BiOkuris is thus a start-up, but with a solid background !

Team

BiOkuris is led by a team combining expertise in Consumer Health, Biotechnology and Medicine.

Read more

François BlondelExecutive Chairman of the Board, Managing Director

Read more

Salvatore ModicaCOO

Read more

Pr. Pierre DesreumauxChairman of the Scientific Board, CSO

Read more

Dr. Véronique MaquetScientific Board

Read more

Pr. Edouard LouisScientific Board

Read more

François LuthersDirector

Read more

Quentin HansenneCFO

Read more

Géry LefebvreSRIW

Read more

Benoit FellinNOSHAQ